UPM Raflatac has introduced the new Raflatac Permanent Medical Device (RPMD) adhesive range, thereby expanding its pharmaceutical and healthcare label solution portfolio for medical device and healthcare industries.
The new range includes labelling solutions for drug/device combination products such as insulin pens, auto-injectors and inhalers.
It also includes blood donation labelling, sterilisation pouches for medical devices, as well as infusion bags and bottles.
When combined with selected paper and film face materials, the new RPMD adhesive is said to create strong adhesion with a tight mandrel hold on glass and plastic.
It offers sterilisation resistance and migration safety, both of which are necessary for healthcare labelling.
UPM Raflatac Specials EMEIA Business Segments and pharma manager Markku Pietarinen said: “With our expanded offering for medical device and healthcare applications, including the RPMD adhesive and a selection of FSC and PEFC certified paper faces for pharmaceutical use, we can continue to address the needs of all our customers.
“These innovative solutions are ideal for the combination product market, which is growing quickly as treatment continues to move away from the hospital and out into the field and the home.”
The newly introduced materials also comply with the EU Medical Device Regulations (MDR) and In-Vitro Diagnostics Regulations (IVDR) published in May.
The new Medical Device Directive aims to implement a Unique Device Identification (UDI) system to identify medical devices in the healthcare supply chain by 2020.
A UDI is a code that would be printed on the label of device packaging or directly on the device in both plain text and machine-readable format.
Image: The new RPMD by UPM Raflatac. Photo: courtesy of UPM Raflatac.